IBDEI0EV ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7178,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,7178,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,7179,0)
 ;;=204.01^^55^577^3
 ;;^UTILITY(U,$J,358.3,7179,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7179,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,7179,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,7179,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,7180,0)
 ;;=204.10^^55^577^16
 ;;^UTILITY(U,$J,358.3,7180,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7180,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,7180,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,7180,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,7181,0)
 ;;=204.11^^55^577^18
 ;;^UTILITY(U,$J,358.3,7181,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7181,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,7181,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,7181,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,7182,0)
 ;;=201.90^^55^577^83
 ;;^UTILITY(U,$J,358.3,7182,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7182,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,7182,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,7182,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,7183,0)
 ;;=785.6^^55^577^89
 ;;^UTILITY(U,$J,358.3,7183,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7183,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,7183,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,7183,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,7184,0)
 ;;=200.20^^55^577^90
 ;;^UTILITY(U,$J,358.3,7184,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7184,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,7184,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,7184,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,7185,0)
 ;;=202.00^^55^577^92
 ;;^UTILITY(U,$J,358.3,7185,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7185,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,7185,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,7185,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,7186,0)
 ;;=200.10^^55^577^91
 ;;^UTILITY(U,$J,358.3,7186,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7186,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,7186,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,7186,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,7187,0)
 ;;=273.3^^55^577^93
 ;;^UTILITY(U,$J,358.3,7187,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7187,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,7187,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,7187,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,7188,0)
 ;;=203.00^^55^577^103
 ;;^UTILITY(U,$J,358.3,7188,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7188,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,7188,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,7188,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,7189,0)
 ;;=203.01^^55^577^105
 ;;^UTILITY(U,$J,358.3,7189,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7189,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,7189,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,7189,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,7190,0)
 ;;=238.6^^55^577^108
 ;;^UTILITY(U,$J,358.3,7190,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7190,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,7190,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,7190,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,7191,0)
 ;;=205.00^^55^577^4
 ;;^UTILITY(U,$J,358.3,7191,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7191,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,7191,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,7191,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,7192,0)
 ;;=205.01^^55^577^6
 ;;^UTILITY(U,$J,358.3,7192,1,0)
 ;;=^358.31IA^5^2
